🇺🇸 FDA
Pipeline program

Placebo tablet matching acetylsalicylic acid, MIGOUTINE 0,5 mg, comprimé pelliculé, ACETYLSALICYLIC ACID , Placebo tablet matching migoutine 0,5 mg, comprimé pelliculé

MHICC-2021-001

Phase 3 small_molecule active

Quick answer

Placebo tablet matching acetylsalicylic acid, MIGOUTINE 0,5 mg, comprimé pelliculé, ACETYLSALICYLIC ACID , Placebo tablet matching migoutine 0,5 mg, comprimé pelliculé for Type 2 diabetic patients with no prior cardiovascular (CV) events is a Phase 3 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Institut für biomedizinische Analytik NMR-Imaging GmbH
Indication
Type 2 diabetic patients with no prior cardiovascular (CV) events
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials